Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 630.00
-4.00 (-0.63%)
Mar 6, 2026, 10:25 AM JST
Cyfuse Biomedical K.K. Revenue
In the year 2025, Cyfuse Biomedical K.K. had annual revenue of 230.00M JPY with 325.93% growth. Cyfuse Biomedical K.K. had revenue of 169.00M in the quarter ending December 31, 2025, with 503.57% growth.
Revenue
230.00M
Revenue Growth
+325.93%
P/S Ratio
27.47
Revenue / Employee
10.95M
Employees
21
Market Cap
6.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.00M | 176.00M | 325.93% |
| Dec 31, 2024 | 54.00M | -7.00M | -11.48% |
| Dec 31, 2023 | 61.00M | -313.00M | -83.69% |
| Dec 31, 2022 | 374.00M | -334.00M | -47.18% |
| Dec 31, 2021 | 708.00M | 571.00M | 416.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 32.52B |
| Morishita Jintan | 12.87B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.40B |
| WDB coco | 4.98B |
| SymBio Pharmaceuticals | 1.31B |